U.S. makes 16- and 17-year-olds eligible for COVID-19 boosters

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. TMUS
6. T
7. SPY
8. UNH
9. AXP
10. BRO

Go back to U.S. makes 16- and 17-year-olds eligible for COVID-19 boosters

Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

December 10, 2021 9:27 AM EST

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in... More